Scholarlink

Background <p>Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC). Abemaciclib was first authorised in the United Kingdom (UK) in 2018 via patient access schemes before approval for routine use. This study assessed the treatment patterns and outcomes of abemaciclib in combination with endocrine therapy in a real-world setting.</p> Methods <p>This was an observational, multi-centre retrospective chart review of women in the UK with HR+, HER2- ABC/MBC treated with abemaciclib plus endocrine therapy during 07/2021 to 05/2022 with <InlineEquation ID="IEq1"> <InlineMediaObject> <ImageObject Color="BlackWhite" FileRef="12885_2025_14526_Article_IEq1.gif" Format="GIF" Height="15" Rendition="HTML" Resolution="72" Type="Linedraw" Width="19" /> </InlineMediaObject> <EquationSource Format="TEX">\(\:\ge\:\)</EquationSource> </InlineEquation>3 months’ follow-up data. Data were summarised using descriptive analyses. Kaplan-Meier methods estimated time to progression (TTP) with 95% confidence intervals (CIs).</p> Results <p>One hundred seventy-four adult women from 9 institutions were included. Median patient age at abemaciclib initiation was 65.2 years. Best tumor response was recorded in 78.2% (<i>n</i> = 136) of patients; 0.7% had complete response, 27.9% had partial response, 59.6% had stable disease and 11.8% had disease progressed. Abemaciclib was associated with a 12-month TTP rate of 81.1% (first line), 68.2% (second line) and 58.2% (third line). The median TTP for patients who received abemaciclib in the first, second, and third line of treatment was: not reached, 27.7 months (95% CI: 11.7 months–not reached), and 19.3 months (95% CI: 7.7–21.9 months), respectively.</p> Conclusions <p>These findings support the benefit of abemaciclib in women with HR+, HER2- ABC/MBC in the real-world and complement data from MONARCH 2 and 3 clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月19日

查看全文
  • Judy King,
  • Walid Fakhouri,
  • Rosalind Jarvis,
  • Waleed Badreldin,
  • Gavin Harper,
  • Carlo Palmieri,
  • Mark Nathan

摘要

Background

Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC). Abemaciclib was first authorised in the United Kingdom (UK) in 2018 via patient access schemes before approval for routine use. This study assessed the treatment patterns and outcomes of abemaciclib in combination with endocrine therapy in a real-world setting.

Methods

This was an observational, multi-centre retrospective chart review of women in the UK with HR+, HER2- ABC/MBC treated with abemaciclib plus endocrine therapy during 07/2021 to 05/2022 with \(\:\ge\:\) 3 months’ follow-up data. Data were summarised using descriptive analyses. Kaplan-Meier methods estimated time to progression (TTP) with 95% confidence intervals (CIs).

Results

One hundred seventy-four adult women from 9 institutions were included. Median patient age at abemaciclib initiation was 65.2 years. Best tumor response was recorded in 78.2% (n = 136) of patients; 0.7% had complete response, 27.9% had partial response, 59.6% had stable disease and 11.8% had disease progressed. Abemaciclib was associated with a 12-month TTP rate of 81.1% (first line), 68.2% (second line) and 58.2% (third line). The median TTP for patients who received abemaciclib in the first, second, and third line of treatment was: not reached, 27.7 months (95% CI: 11.7 months–not reached), and 19.3 months (95% CI: 7.7–21.9 months), respectively.

Conclusions

These findings support the benefit of abemaciclib in women with HR+, HER2- ABC/MBC in the real-world and complement data from MONARCH 2 and 3 clinical trials.